Ocuflox Related Published Studies
Well-designed clinical trials related to Ocuflox (Ofloxacin Ophthalmic)
Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. [2010.12]
Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface. [2010.12]
Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers. [2010.03]
[Human aqueous humor levels of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing.] [2009.11]
A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. [2009.07]
Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients. [2009.03]
Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. [2009.01]
Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial. [2008.03]
A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. [2008.01]
The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. [2007.12]
Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. [2007.09]
Differential Aqueous and Vitreous Concentrations of Moxifloxacin and Ofloxacin After Topical Administration One Hour before Vitrectomy. [2007.08]
Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. [2007.05]
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. [2006.12]
Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. [2005.07]
Three-day application of topical ofloxacin reduces the contamination rate of microsurgical knives in cataract surgery: a prospective randomized study. [2004.07]
Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. [2004.04]
An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. [2004.02]
Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin. [2003.12]
Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. [2003.10]
A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. [2003.08]
A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. [2003.03]
Penetration of topically administered ofloxacin and trimethoprim into aqueous humor. [2002.10]
Penetration of ofloxacin and ciprofloxacin into the aqueous humor of eyes with functioning filtering blebs: a randomized trial. [2001.09]
Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. [2001.03]
[Clinical investigation of 0.3% levofloxacin eyedrops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis] [2000.06]
Comparison of topical 0.3% ofloxacin to fortified tobramycin-cefazolin in the therapy of bacterial keratitis. [2000.05]
Epithelial healing rates with topical ciprofloxacin, ofloxacin, and ofloxacin with artificial tears after photorefractive keratectomy. [2000.05]
Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. [1999.12]
Penetration of ofloxacin and ciprofloxacin in aqueous humor after topical administration. [1999.06]
Collagen shield delivery of ofloxacin to the human eye. [1999.04]
The penetration of ofloxacin into human aqueous humor given by various routes. [1998.01]
Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infection. [1998.01]
Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. [1995.10]
Availability of 0.3% ofloxacin ointment and solution in human conjunctiva and aqueous humor. [1995.03]
Perioperative ofloxacin vs. tobramycin: efficacy in external ocular adnexal sterilization and anterior chamber penetration. [1995.02]
Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes. [1994.03]
Aqueous humor penetration of ofloxacin given by various routes. [1994.01.15]
Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. [1992.12]
Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. [1992.09]
Well-designed clinical trials possibly related to Ocuflox (Ofloxacin Ophthalmic)
Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. [2011.09]
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. [2011.07]
Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections. [2010.12]
Changes in drug susceptibility and the quinolone-resistance determining region of Staphylococcus epidermidis after administration of fluoroquinolones. [2009.11]
[Study of different methods in reducing conjunctival bacteria before cataract surgery] [2009.09.22]
A comparison of fluoroquinolone penetration into human conjunctival tissue. [2008.12]
Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: A prospective randomized multicenter study. [2008.05]
Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. [2007.09]
Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. [2007.06]
[Clinical research of isatis root eyedrops on the acute bacterial conjunctivitis] [2007.01]
Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery. [2005.02]
The challenge of determining aqueous contamination rate in anterior segment intraocular surgery. [2004.04]
Perioperative microbiologic profile of the conjunctiva in photorefractive keratectomy. [2001.01]
Comparison of antibiotic drops placed in the conjunctival cul-de-sac to antibiotic ointment applied to the lid margin in reduction of bacterial colonization on the lid margin. [2000.07]
Comparison of ketorolac tromethamine, diclofenac sodium, and moist drops for ocular pain after radial keratotomy. [1999.08]
Other research related to Ocuflox (Ofloxacin Ophthalmic)
Effectiveness of 1.25 % povidone-iodine combined with topical levofloxacin
against conjunctival flora in intravitreal injection. [2012]
Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. [2011.07]
Efficient penetration into aqueous humor by administration of oral and topical levofloxacin. [2011.06]
Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis. [2010.09]
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. [2010.06]
Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared
with ofloxacin ophthalmic solution 0.3% after topical administration in healthy
adult volunteers. [2010]
Safety of intracameral injection of gatifloxacin, levofloxacin on corneal endothelial structure and viability. [2009.10]
Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. [2009.06.18]
Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system. [2009.04]
Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin. [2009]
Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains. [2008.08]
Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis. [2008.05]
Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. [2008.05]
Penetration of topically applied levofloxacin into eyes with thin-wall filtering bleb after trabeculectomy. [2008.05]
Penetration of topically applied levofloxacin into eyes with thin-wall filtering bleb after trabeculectomy. [2008.05]
Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis. [2007.03]
Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis. [2007.03]
Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration. [2007.02]
Failure of Listeria monocytogenes keratitis to respond to topical ofloxacin. [2006.08]
[The effects of amniotic membrane on corneal penetration of ofloxacin] [2006.07]
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. [2006.05.20]
Fusidic acid vs ofloxacin prophylaxis before cataract surgery. [2005.11]
Safety and efficacy of levofloxacin 1.5% eyedrops in nonhuman primates having penetrating keratoplasty: clinical and laboratory findings. [2005.10]
Reduction of conjunctival bacterial flora by povidone-iodine, ofloxacin and chlorhexidine in an outpatient setting. [2005.06]
Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery. [2005.05]
Flomoxef sodium and levofloxacin concentrations in aqueous humor. [2005.04]
Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. [2005.03]
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. [2004.08]
[Levofloxacin (Tavanic) in the treatment of corneal ulcers] [2003]
Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. [2002.09]
Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis. [2001.11]
The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis. [2001.07]
Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. [2001.06.15]
Effect of topical ciprofloxacin 0.3% and ofloxacin 0.3% on the reduction of bacterial flora on the human conjunctiva. [2000.11]
Effect of a novel mucoadhesive polysaccharide obtained from tamarind seeds on the intraocular penetration of gentamicin and ofloxacin in rabbits. [2000.11]
Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis. [2000.05]
Aqueous humour levels of topically applied ciprofloxacin and ofloxacin in the same subjects. [1999.10]
Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes. [1999.02]
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. [1998.08]
Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration. [1998]
Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye. [1997.08]
Retinal safety of oral and topical ofloxacin in rabbits. [1997.08]
Corneal tissue levels of topically applied ofloxacin. [1997.07]
Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. [1997.05]
Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humours of patients by different topical application modes. [1997]
Ofloxacin penetration into the eye after intravenous and topical administration. [1997]
|
